ChinaTreatyWIPO
11 February 2022

China Joins Two WIPO Treaties, the Hague System and the Marrakesh Treaty

Snow Pine painted by artist Evelyn Hui, mother of Eagle IP’s founder Dr. Jacqueline Lui

It has been two challenging years, yet there are many reasons to still have hope. We wish you a blessed Lunar New Year as we welcome the year of the Tiger.

We wanted to highlight a few new developments in China.

China has joined the Hague System for the International Registration of Industrial Designs, submitting its instrument of accession to the 1999 Geneva Act of the Hague Agreement on February 5, 2022. The Act will go into effect in China on May 5, 2022.

The Hague System provides a way for designers to file a single international design application to register up to 100 designs in up to 94 countries. This helps applicants save time and money on filing separately applications in each jurisdiction. Applicants don’t need to file a national or regional design application first. They can just directly file an international application in the Hague System in one language with one set of fees.

China joining the Hague System gives international designers the option to obtain design patent rights in China through the streamlined Hague System. Chinese designers likewise will have access to the Hague System and access to streamlined design registration in 90+ countries.

As part of this process, China has been updating its design patent laws to comply with Hague System requirements, most notably increasing design patent protection life from 10 years to 15 years in the newest 4th Amendment of the Patent Law. Full details will be available in May. Please note that Hong Kong and Macau are not included.

On the same day, China also signed onto the Marrakesh Treaty, a humanitarian treaty aimed at removing copyright barriers to providing visual impaired people access to published works. The Marrakesh Treaty was adopted on June 27, 2013 and is also administered by the World Intellectual Property Organization (WIPO). It currently has 84 contracting parties, including China, the US, and the European Union.

Eagle IP are experts in patent law and we offer a one-stop service for your global IP needs.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

About the Authors

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

Other Articles

What Kind of Damage Awards Can You Get in China?

16 June 2022
Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in […]

Do Invention and UM Patents Filed on the Same Day Rise and Fall Together?

19 August 2021
Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Seminal Cases by the SPC Recently, the Intellectual Property Division of the Supreme People's Court (SPC) issued a list of seminal (精品) cases. Although China is not a case law country, such seminal cases issued by the SPC have high guiding impact for […]

China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux

24 May 2021
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

9 June 2021
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

Our Past Events

Top crossarrow-right